SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley

Ratings actions from Benzinga: GMT) Celldex Therapeutics Price Target Raised to $57.00/Share From $50.00 by Morgan StanleyRatings actions from Benzinga

CLDX

Related stories